ArticleFrontiers in oncology2026
Efficacy of sacituzumab govitecan in triple-negative breast cancer with hepatic visceral crisis: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is recognized as the most aggressive molecular subtype of breast cancer (BC). The liver is a common site of distant metastasis in BC, and hepatic involvement is associated with accelerated therapeutic resistance and increased mortality risk. Although sacituzumab govitecan (SG) has shown favorable clinical efficacy in the treatment of BC with liver metastasis in the ASCENT randomized controlled trial and real-world studies, its application value in hepatic visceral crisis (HVC) remains inadequately investigated. Herein, we report the clinical course and outcomes of a TNBC patient with diffuse liver metastasis. Following two cycles of SG treatment, the patient achieved significant remission of liver lesions, with a progression-free survival (PFS) of 16.3 months. This case report highlights the necessity of conducting further in-depth studies to explore the application of SG in BC patients with visceral crisis (VC).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.